Measles - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Measles - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Measles - Pipeline Review, H2 2015', provides an overview of the Measles's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Measles and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Measles
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Measles and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Measles products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Measles pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Measles
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Measles pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Measles Overview 8
Therapeutics Development 9
Pipeline Products for Measles - Overview 9
Pipeline Products for Measles - Comparative Analysis 10
Measles - Therapeutics under Development by Companies 11
Measles - Therapeutics under Investigation by Universities/Institutes 12
Measles - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Measles - Products under Development by Companies 16
Measles - Products under Investigation by Universities/Institutes 17
Measles - Companies Involved in Therapeutics Development 18
Beijing Minhai Biotechnology Co., Ltd 18
Beijing Tiantan Biological Products Co., Ltd. 19
Biological E. Limited 20
China National Pharmaceutical Group Corporation 21
Daiichi Sankyo Company, Limited 22
GlaxoSmithKline Plc 23
Organic Vaccines 24
Prometheon Pharma, LLC 25
Sinovac Biotech Ltd. 26
Vical Incorporated 27
Zydus Cadila Healthcare Limited 28
Measles - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
AS-136A - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cell Therapy for Measles, Mumps and Rubella - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ERDRP-0519 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
measles (bivalent) vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
measles + mumps + rubella + varicella vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
measles + mumps + rubella + varicella vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
measles + mumps + rubella + varicella vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
measles + mumps + rubella vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
measles + mumps + rubella vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
measles + mumps + rubella vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
measles + rubella + varicella vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
measles + rubella vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
measles + rubella vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
measles [strain schwarz] + mumps [strain RIT 4385] + rubella [strain wistar RA 27/3] vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
measles vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
VN-0102 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Measles - Recent Pipeline Updates 55
Measles - Dormant Projects 57
Measles - Product Development Milestones 58
Featured News & Press Releases 58
Aug 21, 2008: Vaxfectin Formulated Measles DNA Vaccine Could Address Unmet Need for Infants 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables

Number of Products under Development for Measles, H2 2015 9
Number of Products under Development for Measles - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Investigation by Universities/Institutes, H2 2015 17
Measles - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 18
Measles - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2015 19
Measles - Pipeline by Biological E. Limited, H2 2015 20
Measles - Pipeline by China National Pharmaceutical Group Corporation, H2 2015 21
Measles - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 22
Measles - Pipeline by GlaxoSmithKline Plc, H2 2015 23
Measles - Pipeline by Organic Vaccines, H2 2015 24
Measles - Pipeline by Prometheon Pharma, LLC, H2 2015 25
Measles - Pipeline by Sinovac Biotech Ltd., H2 2015 26
Measles - Pipeline by Vical Incorporated, H2 2015 27
Measles - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 28
Assessment by Monotherapy Products, H2 2015 29
Assessment by Combination Products, H2 2015 30
Number of Products by Stage and Target, H2 2015 32
Number of Products by Stage and Mechanism of Action, H2 2015 34
Number of Products by Stage and Route of Administration, H2 2015 36
Number of Products by Stage and Molecule Type, H2 2015 38
Measles Therapeutics - Recent Pipeline Updates, H2 2015 55
Measles - Dormant Projects, H2 2015 57